Erythrocyte-Binding Therapeutics for Immune Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for immunotolerization and drug delivery face challenges in effectively suppressing immune responses to transplanted tissues and autoimmune diseases, with existing vaccines and treatments often inducing adverse reactions and limited efficacy.
Innovation Solution
Development of pharmaceutically acceptable compositions comprising molecular fusions of tolerogenic antigens combined with erythrocyte-binding moieties, such as peptides or antibodies, that specifically bind to erythrocytes, allowing for targeted presentation of antigens to the immune system to induce tolerance and extend the circulation half-life of therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional vaccines and immunosuppressive treatments are used to suppress immune responses, then immune rejection can be reduced, but adverse reactions increase and efficacy is limited
Solution Approach 1:
The patent uses erythrocytes as intermediary carriers to deliver tolerogenic antigens to the immune system. The erythrocyte-binding moiety specifically targets erythrocytes, which then present the tolerogenic antigen in a controlled manner, mediating the immune tolerance induction process while avoiding the harmful side effects of conventional immunosuppressants
Solution Approach 2:
The invention creates artificial tolerogenic antigens that are copied onto erythrocyte surfaces through fusion proteins or conjugates. These copied antigens mimic natural self-antigens and are presented to the immune system in a way that induces tolerance without triggering adverse reactions, effectively copying the beneficial effect of self-tolerance
2Productivity
If therapeutic agents are administered to achieve drug delivery, then treatment efficacy is achieved, but circulation half-life is limited
Solution Approach 1:
The patent merges therapeutic agents with erythrocyte-binding moieties to create fusion proteins or conjugates. This combination allows the therapeutic agent to hitchhike on erythrocytes throughout circulation, extending its circulation half-life from minutes to days while maintaining its therapeutic function and improving delivery efficacy
Solution Approach 2:
The erythrocyte-binding moiety serves multiple functions: it extends circulation half-life, targets the therapeutic agent to specific tissues, and can simultaneously deliver multiple different therapeutic agents. This multi-functionality improves overall drug delivery efficacy while solving the limited half-life problem
3Reliability
If fusion molecules are used to induce immunotolerance, then antigen-specific tolerance is achieved, but molecular complexity increases
Solution Approach 1:
The fusion molecule is segmented into distinct functional domains: an erythrocyte-binding domain (such as a peptide or antibody fragment) and a tolerogenic antigen domain. This segmentation allows each domain to perform its specific function independently while being part of a unified molecule, achieving immunotolerance with manageable molecular complexity
Solution Approach 2:
The erythrocyte acts as an intermediary that simplifies the complex process of inducing immunotolerance. Instead of directly presenting the tolerogenic antigen to immune cells (which requires complex molecular interactions), the erythrocyte serves as a natural, biocompatible carrier that presents the antigen in a physiologically relevant manner, reducing the apparent molecular complexity of the system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively reduces adaptive immune responses, increases the half-life of therapeutic agents in circulation, and induces antigen-specific tolerance, potentially preventing rejection of transplanted tissues and autoimmune reactions, while ensuring safe and effective drug delivery.
Implementation Method 1
an erythrocyte-binding moiety that specifically binds an erythrocyte in the patient
Data Source
Figure 1a~1c
Figure 2a~2k
Figure 3~4B
AI summary
Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immimotolerance may be created by use of the fusions and choice of an antigen on a substance for which tolerance is desired.